Page 4 - Aytu Bioscience News Today

Following the market opening Thursday, the Dow traded down 0.12% to 30,033.62 while the NASDAQ rose 0.32% to 12,378.96. The S&P also rose, gaining 0.02% to 3,673.72.

Neos Therapeutics Inc (NASDAQ: NEOS) in an all-stock merger transaction. The boards of both companies have approved the deal. Upon the closing of the merger, Neos shareholders will receive 0.1088 shares of Aytu for each share they hold in Neos, after taking into account the 1-for-10 reverse split of Aytu shares that took effect Dec. 8. The deal terms value Neos at $44.9 million. Neos shareholders will end up owning a 30% stake in Aytu. "The combined entity will have an increased footprint in ...

Midway through trading Thursday, the Dow traded down 0.19% to 30,012.81 while the NASDAQ rose 0.47% to 12,396.34. The S&P also fell, dropping 0.03% to 3,671.66.

Toward the end of trading Thursday, the Dow traded down 0.41% to 29,945.74 while the NASDAQ rose 0.29% to 12,375.19. The S&P also fell, dropping 0.30% to 3,661.97.

Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos' established,

m ET ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that they have entered into a definitive merger agreement pursuant to which Neos will merg...

The Price And Volume Action In Aytu BioScience's Stock Today Aytu BioScience (NASDAQ: AYTU) is currently up 26.35% to a price of $8.69. The stock’s current volume for the day is 3.76 million, which is approximately 1230.44% of its previous 30-day average volume of 305.25 thousand.

60 Stocks Moving In Thursdays Mid-Day Session Benzinga 12/10/2020 Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner, EOC Pharma will commence a new Phase 2 clinical trial of Immuteps eftilagimod alpha in up to 152 metastatic breast cancer patients in China. Immutep said the study follows encouraging data reported by it in its APIAC Phase 2b study announced at the end of March and presented at the SABCS. Greenwich LifeSciences, In...

/PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics,...